Asthma
COPD
Pulmonary
Pulmonary: Page 3
Testing begins for possible chronic cough cure
Two global clinical trials will determine efficacy, safety and tolerability of treatment related to IPF.
August 21, 2026
A pathological look at lung, autoimmune diseases
Dysfunctional pulmonary tissue-resident immune cells could alter genetics and increase risk of developing certain life-threatening conditions.
August 11, 2026
TBX4 gene critical in pediatric PH
Genetics research identified lack of function is linked to early development of pulmonary hypertension.
August 10, 2026
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2026 to 2035.
July 21, 2026
CDC mold infection report: Rising health threat
Localized findings warrant public health concern of invasive mold disease among at-risk individuals.
August 7, 2026
Protein restoration may reverse lung disease
Preclinical models showed increased levels of BMP3 can undo damage associated with pulmonary arterial hypertension.
August 7, 2026
RNA-based testing can improve diagnostic accuracy, treatment selection in NSCLC patients
Real-world study demonstrates the diversity and complexity of genomic mutations causing
MET
exon 14 skipping.
July 28, 2026
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2026 to 2035.
July 21, 2026
TLR5 deficiency linked to IPF risk
Identification of key receptor could lead to new therapeutic target to prevent or slow pulmonary fibrosis.
July 27, 2026
How lung cancer can hijack the nervous system
Disrupting the tumor-to-brain connection can reduce the risk of developing cachexia and improve patient outcomes.
July 24, 2026
Vitronectin opens door to novel PF therapies
Discovery of the protein’s critical role in lung scarring could improve healing for patients who have pulmonary fibrosis.
July 23, 2026
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2026 to 2035.
July 21, 2026
Silicosis breakthrough: Epithelial cells are key activators
Scientists disprove previous assumptions that the incurable lung disease is initiated by immune cells.
July 16, 2026
Rare lung disease linked to TMEM63B gene mutation
Breakthrough research shows the severe childhood lung disease is caused by biallelic loss-of-function TMEM63B variant.
July 15, 2026
Genetic testing alters pulmonary care
Assessing telomere length in patients with pulmonary fibrosis could improve diagnosis and condition management.
July 9, 2026
Previous Page
Page 3 of 30
Next Page
Most Popular
Hidden immune cell unlocks novel SCLC treatment approach
Primary care initiative tackles asthma rescue inhaler overuse
Mepolizumab reduces systemic corticosteroid exposure in COPD patients
Long-term impact of pediatric TB patients
COPD treatment falls short in phase 2 proof-of-concept trial
Merck begins phase 3 study for ensifentrine COPD treatment